The Saline v Albumin Fluid Evaluation ( SAFE ) trial reported patient-centred outcomes at 28 days in 6933 patients assigned to fluid resuscitation with either 4 % albumin or 0.9 % saline ; the Crystalloid v Hydroxyethyl Starch Trial ( CHEST ) reported patient-centred outcomes at 28 days in 6644 patients assigned to fluid resuscitation with either 6 % HES ( 130/0 .4 ) or 0.9 % saline .